Laleh Mahmoudi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laleh Mahmoudi has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Ramin Niknam
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
25 shared publications - Dena Firouzabadi
Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
6 shared publications - Ali Akbari
Department of Anesthesiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications - Amirreza Dehghanian
Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications - Mohammad Reza Fattahi
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications - Mojtaba Mojtahedzadeh
Department of Clinical Pharmacy, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
3 shared publications
Latest Publications
- 31 December 2025
- Published by Elsevier in Parasitology International
- Vol. 112, 103229
Evaluating the efficacy of Glucantime and determinants of treatment success in cutaneous leishmaniasis: A retrospective study
- 31 December 2025
- Published by Elsevier in Parasitology International
- Vol. 112, 103229
Evaluating the efficacy of Glucantime and determinants of treatment success in cutaneous leishmaniasis: A retrospective study
- Open Access
- 16 June 2025
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 31 (3) , 330-337
Renal Impact of a High-Loading Dose of Amikacin in Critically Ill Patients
Background: Aminoglycosides are potent bactericidal antibiotics primarily employed for gram-negative infections. However, they face limitations due to potential renal toxicity when administered at high doses. This study aimed to assess the nephrotoxicity of amikacin (AMK) at two distinct dosage levels over seven days in critically ill patients, utilizing renal-specific biomarkers. Methods: Critically ill patients with sepsis, severe sepsis, or septic shock were randomly assigned to two treatment groups receiving AMK in combination with a broad-spectrum β-lactam antibiotic according to antibiogram results. Disease severity was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores. Renal function was monitored through serum creatinine (SCr) and kidney injury biomarkers (NGAL and IL-18) measurements. Results: Among the 40 patients completing the study, the two groups had no significant differences in APACHE II (P = 0.39) and SOFA scores (P = 0.30). Baseline plasma creatinine levels exhibited no significant within-group differences. While NGAL levels in group 1(high dose AMK) significantly increased on day 3, no significant differences were observed between the groups in all four measurements (P = 0.03). Urinary IL-18 levels within groups demonstrated a significant increase peaking on day 3, with no significant within-group differences over the 7-day follow-up. Conclusion: The findings suggest that higher doses of AMK may be administered with a similar effect of low-dose AMK on renal function, as assessed by the RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage kidney disease), a classification system used to evaluate acute kidney injury (AKI) severity in critically ill patients with sepsis.
- 16 June 2025
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 31 (3) , 330-337
Open AccessRenal Impact of a High-Loading Dose of Amikacin in Critically Ill Patients
Background: Aminoglycosides are potent bactericidal antibiotics primarily employed for gram-negative infections. However, they face limitations due to potential renal toxicity when administered at high doses. This study aimed to assess the nephrotoxicity of amikacin (AMK) at two distinct dosage levels over seven days in critically ill patients, utilizing renal-specific biomarkers. Methods: Critically ill patients with sepsis, severe sepsis, or septic shock were randomly assigned to two treatment groups receiving AMK in combination with a broad-spectrum β-lactam antibiotic according to antibiogram results. Disease severity was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores. Renal function was monitored through serum creatinine (SCr) and kidney injury biomarkers (NGAL and IL-18) measurements. Results: Among the 40 patients completing the study, the two groups had no significant differences in APACHE II (P = 0.39) and SOFA scores (P = 0.30). Baseline plasma creatinine levels exhibited no significant within-group differences. While NGAL levels in group 1(high dose AMK) significantly increased on day 3, no significant differences were observed between the groups in all four measurements (P = 0.03). Urinary IL-18 levels within groups demonstrated a significant increase peaking on day 3, with no significant within-group differences over the 7-day follow-up. Conclusion: The findings suggest that higher doses of AMK may be administered with a similar effect of low-dose AMK on renal function, as assessed by the RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage kidney disease), a classification system used to evaluate acute kidney injury (AKI) severity in critically ill patients with sepsis.
- Open Access
- 19 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70619
Effect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II–IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial
Background and Aims: Peripheral neuropathy is a major side effect of oxaliplatin‐based chemotherapy. The aim of this placebo‐controlled double‐blind randomized study was to evaluate the effect of melatonin on prevention of oxaliplatin induced peripheral neuropathy (OXIPN) in patients receiving oxaliplatin for colorectal cancer. Methods: Patients with stage II–IV colorectal cancer, who were to receive oxaliplatin‐based chemotherapy, were enrolled according to the inclusion criteria and randomly assigned to take either melatonin (20 mg/day) or placebo, during chemotherapy and 1 month after. Neuropathy was assessed by several patient‐ and physician‐based reports, including the National Cancer Institute Common Terminology Criteria for Adverse Events scale (NCI‐CTCAE), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy‐Induced Peripheral Neuropathy 20 (EORTC QLQ‐CIPN20) scale, and oxaliplatin specific scale (OSS). Results: From a total of 80 selected patients, 54 completed the study and were evaluated for the final analysis. Grade 3 neuropathy measured by NCI‐CTCAE and OSS in the melatonin arm was significantly lower than the placebo group. But according to EORTC QLQ‐CIPN20 scale, no statistically significant difference was observed between the groups. In addition, melatonin use did not improve patients' quality of life compared with placebo. Conclusion: Reduction in grade 3 neuropathy based on NCI‐CTCAE and OSS can be of great importance, as it is the higher‐grade neuropathy that may lead to functional impairment. Given that to date no medication has been approved for prevention of OXIPN and considering the limited number of patients in the present study, conducting a larger clinical trial on the effect of melatonin may lead to beneficial results in this group of patients. Trial Registration: Study registered (Date: 23 July, 2018) in the Iranian Registry of Clinical Trials (IRCT); IRCT20170326033139N1 ( https://www.irct.ir/search/result?query=IRCT20170326033139N1 )
- 19 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70619
Open AccessEffect of Melatonin on Oxaliplatin Induced Neuropathy in Patients Receiving Folfox Chemotherapy Regimens for Stage II–IV Colorectal Cancer: A Randomized, Placebo Controlled, Double Blind Trial
Background and Aims: Peripheral neuropathy is a major side effect of oxaliplatin‐based chemotherapy. The aim of this placebo‐controlled double‐blind randomized study was to evaluate the effect of melatonin on prevention of oxaliplatin induced peripheral neuropathy (OXIPN) in patients receiving oxaliplatin for colorectal cancer. Methods: Patients with stage II–IV colorectal cancer, who were to receive oxaliplatin‐based chemotherapy, were enrolled according to the inclusion criteria and randomly assigned to take either melatonin (20 mg/day) or placebo, during chemotherapy and 1 month after. Neuropathy was assessed by several patient‐ and physician‐based reports, including the National Cancer Institute Common Terminology Criteria for Adverse Events scale (NCI‐CTCAE), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy‐Induced Peripheral Neuropathy 20 (EORTC QLQ‐CIPN20) scale, and oxaliplatin specific scale (OSS). Results: From a total of 80 selected patients, 54 completed the study and were evaluated for the final analysis. Grade 3 neuropathy measured by NCI‐CTCAE and OSS in the melatonin arm was significantly lower than the placebo group. But according to EORTC QLQ‐CIPN20 scale, no statistically significant difference was observed between the groups. In addition, melatonin use did not improve patients' quality of life compared with placebo. Conclusion: Reduction in grade 3 neuropathy based on NCI‐CTCAE and OSS can be of great importance, as it is the higher‐grade neuropathy that may lead to functional impairment. Given that to date no medication has been approved for prevention of OXIPN and considering the limited number of patients in the present study, conducting a larger clinical trial on the effect of melatonin may lead to beneficial results in this group of patients. Trial Registration: Study registered (Date: 23 July, 2018) in the Iranian Registry of Clinical Trials (IRCT); IRCT20170326033139N1 ( https://www.irct.ir/search/result?query=IRCT20170326033139N1 )
- Open Access
- 11 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (15) , e42103
The effect of calcitriol and cholecalciferol on inflammatory markers in periprocedural myocardial injury: A randomized controlled trial
Background: Inflammation is an important factor in the development of cardiac injury during and after percutaneous coronary intervention (PCI). Vitamin D receptors play a significant role in the cardiovascular system and have anti-inflammatory effects. Hence, our goal was to evaluate the impact of calcitriol and cholecalciferol as vitamin D receptors agonists on inflammatory biomarkers in patients who are undergoing elective PCI. Methods: In this controlled clinical trial, patients undergoing elective PCI were randomly assigned to receive either calcitriol and cholecalciferol or were placed in the control group from July 2021 to November 2022. Calcitriol and cholecalciferol were administered at doses of 1 mcg and 300,000 international units, respectively, before the procedure. High-sensitive C-reactive protein (hs-CRP) was evaluated as the main inflammatory biomarker and other relevant clinical and laboratory data were also included. Results: During the study, 180 patients were allocated into three groups, each consisting of 60 patients, with a mean age of 62.26 ± 8.73 years. The prevalence of the underlying conditions was not different among the groups. After 24 hours, hs-CRP levels were lower (P = .012), and a significantly lower increase from baseline was observed (P = .003) in the group that received calcitriol. However, no significant differences were observed in Troponin I and creatine kinase-MB levels (P > .05). Conclusions: Administration of calcitriol was associated with significantly lower levels of hs-CRP, the main cardiac inflammatory marker, in patients undergoing elective PCI. Further clinical studies with a larger sample size are needed to assess the clinical impact of this anti-inflammatory effect.
- 11 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (15) , e42103
Open AccessThe effect of calcitriol and cholecalciferol on inflammatory markers in periprocedural myocardial injury: A randomized controlled trial
Background: Inflammation is an important factor in the development of cardiac injury during and after percutaneous coronary intervention (PCI). Vitamin D receptors play a significant role in the cardiovascular system and have anti-inflammatory effects. Hence, our goal was to evaluate the impact of calcitriol and cholecalciferol as vitamin D receptors agonists on inflammatory biomarkers in patients who are undergoing elective PCI. Methods: In this controlled clinical trial, patients undergoing elective PCI were randomly assigned to receive either calcitriol and cholecalciferol or were placed in the control group from July 2021 to November 2022. Calcitriol and cholecalciferol were administered at doses of 1 mcg and 300,000 international units, respectively, before the procedure. High-sensitive C-reactive protein (hs-CRP) was evaluated as the main inflammatory biomarker and other relevant clinical and laboratory data were also included. Results: During the study, 180 patients were allocated into three groups, each consisting of 60 patients, with a mean age of 62.26 ± 8.73 years. The prevalence of the underlying conditions was not different among the groups. After 24 hours, hs-CRP levels were lower (P = .012), and a significantly lower increase from baseline was observed (P = .003) in the group that received calcitriol. However, no significant differences were observed in Troponin I and creatine kinase-MB levels (P > .05). Conclusions: Administration of calcitriol was associated with significantly lower levels of hs-CRP, the main cardiac inflammatory marker, in patients undergoing elective PCI. Further clinical studies with a larger sample size are needed to assess the clinical impact of this anti-inflammatory effect.
- Open Access
- 27 February 2025
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 20 (1)
A Randomized, Placebo-Controlled Study Investigating the Impact of α-pinene on Symptom Relief, Quality of Life and Inflammatory Markers in Individuals with Ulcerative Colitis
Background: Given the limited evidence on the efficacy of α-pinene, a herbal terpenoid, in the management of ulcerative colitis (UC), this clinical trial aims to investigate the effects of α-pinene compared to a placebo. Methods: Eligible UC patients were randomized to receive either α-pinene or a placebo, alongside their routine pharmacologic regimen, for two months. Quality of life (QoL) and disease severity were assessed using the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ) and the Crohn’s and UC Questionnaire-8 (CUCQ-8), respectively. Additionally, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured as inflammatory markers. Results: The QoL was significantly improved in the α-pinene group compared to the placebo group (P = 0.02). Several items of the CUCQ-8 also showed better outcomes in the α-pinene group. However, there were no significant differences in ESR and CRP levels between the two groups (P = 0.64 and P = 0.78, respectively). Conclusions: α-pinene may be considered as a dietary supplement to enhance QoL and alleviate several symptoms in patients with UC.
- 27 February 2025
- Published by Brieflands in Jundishapur Journal of Natural Pharmaceutical Products
- Vol. 20 (1)
Open AccessA Randomized, Placebo-Controlled Study Investigating the Impact of α-pinene on Symptom Relief, Quality of Life and Inflammatory Markers in Individuals with Ulcerative Colitis
Background: Given the limited evidence on the efficacy of α-pinene, a herbal terpenoid, in the management of ulcerative colitis (UC), this clinical trial aims to investigate the effects of α-pinene compared to a placebo. Methods: Eligible UC patients were randomized to receive either α-pinene or a placebo, alongside their routine pharmacologic regimen, for two months. Quality of life (QoL) and disease severity were assessed using the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ) and the Crohn’s and UC Questionnaire-8 (CUCQ-8), respectively. Additionally, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured as inflammatory markers. Results: The QoL was significantly improved in the α-pinene group compared to the placebo group (P = 0.02). Several items of the CUCQ-8 also showed better outcomes in the α-pinene group. However, there were no significant differences in ESR and CRP levels between the two groups (P = 0.64 and P = 0.78, respectively). Conclusions: α-pinene may be considered as a dietary supplement to enhance QoL and alleviate several symptoms in patients with UC.
- Open Access
- 8 October 2024
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 12 (4)
Health-Related Quality of Life (HRQoL) in COVID-19 Patients After Recovering from the Acute Infection
Background: Nearly four years after the COVID-19 outbreak, its burden persists, with long-term physical and mental impacts still being discovered. Objectives: Given that these effects may vary across different periods post-infection and in diverse cultural, medical, and economic settings, we aimed to evaluate the health-related quality of life (HRQoL) in Iranian patients six months after acute infection. Methods: A total of 194 infected patients were enrolled and re-evaluated six months after the onset of acute infection. Health-related quality of life was assessed using the validated EQ-5D-3L questionnaire. Results: The mean age of patients was 50.1 ± 15.8 years, with a female-to-male ratio of 1.04. Diabetes mellitus and hypertension were the most common comorbidities. Significant impairment was observed in all categories of HRQoL after recovery from acute COVID-19 infection (P-value < 0.05). Female gender, older age, and intensive care unit admissions were independent factors associated with worsened health status post-recovery. The overall reduction in post-COVID-19 infection quality of life (QoL) score was 25%. Conclusions: The mental and physical burden of COVID-19 in our study population was considerable. Comorbid conditions and a lack of supportive measures post-infection, especially in a low-income country, may contribute to the long-term effects of COVID-19.
- 8 October 2024
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 12 (4)
Open AccessHealth-Related Quality of Life (HRQoL) in COVID-19 Patients After Recovering from the Acute Infection
Background: Nearly four years after the COVID-19 outbreak, its burden persists, with long-term physical and mental impacts still being discovered. Objectives: Given that these effects may vary across different periods post-infection and in diverse cultural, medical, and economic settings, we aimed to evaluate the health-related quality of life (HRQoL) in Iranian patients six months after acute infection. Methods: A total of 194 infected patients were enrolled and re-evaluated six months after the onset of acute infection. Health-related quality of life was assessed using the validated EQ-5D-3L questionnaire. Results: The mean age of patients was 50.1 ± 15.8 years, with a female-to-male ratio of 1.04. Diabetes mellitus and hypertension were the most common comorbidities. Significant impairment was observed in all categories of HRQoL after recovery from acute COVID-19 infection (P-value < 0.05). Female gender, older age, and intensive care unit admissions were independent factors associated with worsened health status post-recovery. The overall reduction in post-COVID-19 infection quality of life (QoL) score was 25%. Conclusions: The mental and physical burden of COVID-19 in our study population was considerable. Comorbid conditions and a lack of supportive measures post-infection, especially in a low-income country, may contribute to the long-term effects of COVID-19.
- 23 September 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (3) , 2945-2960
Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial
Nephrotoxicity is one of the most common complications of vancomycin use in clinical practice. Silymarin has potential to be a renoprotective agent for nephrotoxic drugs due to its antioxidant, anti-inflammatory, and anti-apoptotic effects. The aim of this clinical study is evaluating the potential effects of silymarin on preventing vancomycin nephrotoxicity. A multicenter, randomized, double-blinded, placebo-controlled, clinical trial was conducted on patients with the indication of systemic vancomycin for at least 7 days. Patients were screened daily and those who met the inclusion criteria were selected and randomly assigned into either silymarin or placebo groups. Accordingly, 140 mg silymarin tablet (Livergol®) or placebo was given orally three times daily. Silymarin or placebo were provided in conjunction with vancomycin for at least 7 days. If vancomycin therapy was extended beyond 7 days, the administration of silymarin or placebo was continued until the end of vancomycin treatment. Malondialdehyde, glutathione, and total antioxidant capacity were measured in the serum on days 0 and 7. A trough level of vancomycin was assessed 30 min before the fifth dose of vancomycin. Acute kidney injury (AKI) was monitored in each patient daily during the course of vancomycin treatment. The causality assessment of all identified cases of vancomycin associated AKI was performed by the Naranjo scale. The primary endpoint was vancomycin nephrotoxicity. It was defined based on the KDIGO 2012 criteria for AKI as either an increase of 0.3 units or more in serum creatinine level during 48 h or 50% (1.5-fold) or more during 7 days compared to baseline values. During the study period, 34 patients in the silymarin group and 32 patients in the placebo group completed the clinical trial. Demographic, baseline clinical, and laboratory characteristics were comparable between placebo and silymarin groups. The number of patients with AKI on days 5, 6, 7, 11,12, 13, and 14 in the placebo group was significantly higher than that in the silymarin group (p-value < 0.05). The incidence of acute tubular injury on the day 5 and 7 of vancomycin treatment was significantly lower in the silymarin group (p-value = 0.005 and p-value = 0.032, respectively). Antioxidant indexes including serum total antioxidant capacity and glutathione significantly increased in the silymarin group (p-value < 0.001 for both indexes). In contrast, serum malondialdehyde as an end product of lipid peroxidation pathway significantly decreased in the silymarin group during 7 days (p-value < 0.001). The results of the present pilot, clinical trial suggested that silymarin co-administration may prevent vancomycin nephrotoxicity.
- 23 September 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (3) , 2945-2960
Protective effects of silymarin on preventing vancomycin nephrotoxicity in infectious patients: a randomized, double-blinded, placebo-controlled, pilot clinical trial
Nephrotoxicity is one of the most common complications of vancomycin use in clinical practice. Silymarin has potential to be a renoprotective agent for nephrotoxic drugs due to its antioxidant, anti-inflammatory, and anti-apoptotic effects. The aim of this clinical study is evaluating the potential effects of silymarin on preventing vancomycin nephrotoxicity. A multicenter, randomized, double-blinded, placebo-controlled, clinical trial was conducted on patients with the indication of systemic vancomycin for at least 7 days. Patients were screened daily and those who met the inclusion criteria were selected and randomly assigned into either silymarin or placebo groups. Accordingly, 140 mg silymarin tablet (Livergol®) or placebo was given orally three times daily. Silymarin or placebo were provided in conjunction with vancomycin for at least 7 days. If vancomycin therapy was extended beyond 7 days, the administration of silymarin or placebo was continued until the end of vancomycin treatment. Malondialdehyde, glutathione, and total antioxidant capacity were measured in the serum on days 0 and 7. A trough level of vancomycin was assessed 30 min before the fifth dose of vancomycin. Acute kidney injury (AKI) was monitored in each patient daily during the course of vancomycin treatment. The causality assessment of all identified cases of vancomycin associated AKI was performed by the Naranjo scale. The primary endpoint was vancomycin nephrotoxicity. It was defined based on the KDIGO 2012 criteria for AKI as either an increase of 0.3 units or more in serum creatinine level during 48 h or 50% (1.5-fold) or more during 7 days compared to baseline values. During the study period, 34 patients in the silymarin group and 32 patients in the placebo group completed the clinical trial. Demographic, baseline clinical, and laboratory characteristics were comparable between placebo and silymarin groups. The number of patients with AKI on days 5, 6, 7, 11,12, 13, and 14 in the placebo group was significantly higher than that in the silymarin group (p-value < 0.05). The incidence of acute tubular injury on the day 5 and 7 of vancomycin treatment was significantly lower in the silymarin group (p-value = 0.005 and p-value = 0.032, respectively). Antioxidant indexes including serum total antioxidant capacity and glutathione significantly increased in the silymarin group (p-value < 0.001 for both indexes). In contrast, serum malondialdehyde as an end product of lipid peroxidation pathway significantly decreased in the silymarin group during 7 days (p-value < 0.001). The results of the present pilot, clinical trial suggested that silymarin co-administration may prevent vancomycin nephrotoxicity.
- Open Access
- 4 August 2024
- Published by Brieflands in Shiraz E-Medical Journal
- Vol. 25 (9)
Risk Factors for Decreased Bone Density in Adults with Celiac Disease
Background: Celiac disease (CD) is an autoimmune disease characterized by inflammation in the intestine, causing atrophy of the mucosal villi of the small intestine. Celiac disease can manifest with various signs and symptoms, including extra-intestinal symptoms such as osteopenia and osteoporosis. Objectives: Our study aimed to determine the frequency of osteopenia/osteoporosis in newly diagnosed CD cases and to evaluate the effect of different independent variables on the development of osteopenia/osteoporosis in these patients. Methods: Adult patients with CD who were referred to a celiac clinic were evaluated for osteopenia/osteoporosis using dual-energy X-ray absorptiometry. This cross-sectional analytical study took place from October 2017 to July 2022. Logistic regression analysis was used to assess the odds ratio (OR) of different independent variables for osteopenia/osteoporosis. Results: A total of 302 patients enrolled in this study, with 64.2% being female and 35.8% male. The mean ± SD age was 29.73 ± 12.39. Overall, 71.2% of patients had osteopenia or osteoporosis. The odds of developing osteopenia/osteoporosis were significantly higher in participants older than 30 years (OR: 2.19; 95% CI: 1.22 - 3.92; P = 0.008), underweight patients (OR: 2.38; 95% CI: 1.30 - 4.34; P = 0.005), and those with histologically severe atrophy (OR: 2.22; 95% CI: 1.14 - 4.32; P = 0.019). The mean ± SD serum levels of 25-hydroxy vitamin D in CD patients without and with osteopenia/osteoporosis were 34.0 ± 17.1 ng/mL and 25.8 ± 14.2 ng/mL, respectively. Participants with normal levels of 25-hydroxy vitamin D had a significantly lower OR of developing osteopenia/osteoporosis than patients with vitamin D deficiency (OR: 0.37; 95% CI: 0.21 - 0.62; P < 0.001). Other variables, including gender, anti-tTG levels, and GI manifestations, did not significantly increase the OR of developing osteopenia/osteoporosis. Conclusions: The present study showed that increasing age, weight loss, severe villous atrophy, and low levels of vitamin D can significantly increase the OR of developing osteopenia/osteoporosis in CD patients. Until further studies are conducted, bone mineral density (BMD) evaluation is especially recommended in these high-risk subgroups of CD patients.
- 4 August 2024
- Published by Brieflands in Shiraz E-Medical Journal
- Vol. 25 (9)
Open AccessRisk Factors for Decreased Bone Density in Adults with Celiac Disease
Background: Celiac disease (CD) is an autoimmune disease characterized by inflammation in the intestine, causing atrophy of the mucosal villi of the small intestine. Celiac disease can manifest with various signs and symptoms, including extra-intestinal symptoms such as osteopenia and osteoporosis. Objectives: Our study aimed to determine the frequency of osteopenia/osteoporosis in newly diagnosed CD cases and to evaluate the effect of different independent variables on the development of osteopenia/osteoporosis in these patients. Methods: Adult patients with CD who were referred to a celiac clinic were evaluated for osteopenia/osteoporosis using dual-energy X-ray absorptiometry. This cross-sectional analytical study took place from October 2017 to July 2022. Logistic regression analysis was used to assess the odds ratio (OR) of different independent variables for osteopenia/osteoporosis. Results: A total of 302 patients enrolled in this study, with 64.2% being female and 35.8% male. The mean ± SD age was 29.73 ± 12.39. Overall, 71.2% of patients had osteopenia or osteoporosis. The odds of developing osteopenia/osteoporosis were significantly higher in participants older than 30 years (OR: 2.19; 95% CI: 1.22 - 3.92; P = 0.008), underweight patients (OR: 2.38; 95% CI: 1.30 - 4.34; P = 0.005), and those with histologically severe atrophy (OR: 2.22; 95% CI: 1.14 - 4.32; P = 0.019). The mean ± SD serum levels of 25-hydroxy vitamin D in CD patients without and with osteopenia/osteoporosis were 34.0 ± 17.1 ng/mL and 25.8 ± 14.2 ng/mL, respectively. Participants with normal levels of 25-hydroxy vitamin D had a significantly lower OR of developing osteopenia/osteoporosis than patients with vitamin D deficiency (OR: 0.37; 95% CI: 0.21 - 0.62; P < 0.001). Other variables, including gender, anti-tTG levels, and GI manifestations, did not significantly increase the OR of developing osteopenia/osteoporosis. Conclusions: The present study showed that increasing age, weight loss, severe villous atrophy, and low levels of vitamin D can significantly increase the OR of developing osteopenia/osteoporosis in CD patients. Until further studies are conducted, bone mineral density (BMD) evaluation is especially recommended in these high-risk subgroups of CD patients.
- Open Access
- 10 June 2024
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 12 (3)
Variants of Ascitic Fluid Bacterial Infections and Clinical Outcomes in Patients with Liver Cirrhosis
Background: Ascitic fluid infection (AFI) is the most common bacterial infection in patients with cirrhosis and has several variants, including spontaneous bacterial peritonitis (SBP), bacterascites (BA), and culture-negative neutrocytic ascites (CNNA). Objectives: To date, there has been disagreement about the differences in clinical features and outcomes of these variants of AFI, and there are still few studies in this area. Methods: A cross-sectional study was conducted at a referral hospital from June 2018 to September 2022. All cirrhotic patients with ascites were evaluated for the presence of AFI. Patients with AFI were divided into SBP, BA, and CNNA variants. Non-AFI participants were also evaluated as a comparison group. The outcomes, as well as the clinical and laboratory characteristics of the variants of AFI, were compared. Kaplan-Meier curves and Cox regression analysis were used for survival analysis. Results: A total of 466 patients were studied, of which 132 (28.33%) were in the AFI group and 334 (71.67%) were in the non-AFI group. In the AFI group, 64 (48.48%) had SBP, 43 (32.58%) had CNNA, and 25 (18.94%) had BA. The most common bacteria causing AFI was Escherichia coli. SBP (HR 2.43; 95% CI 1.36 - 4.36; P = 0.003) significantly increased the risk of mortality, while CNNA and BA did not significantly increase this risk. The presence of hepatic encephalopathy and female gender also significantly increased the risk of mortality. Conclusions: The mortality risk was higher in patients with SBP compared to other types of AFI. This study also showed differences in clinical characteristics and laboratory parameters among the three types of AFI. Further research is recommended.
- 10 June 2024
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 12 (3)
Open AccessVariants of Ascitic Fluid Bacterial Infections and Clinical Outcomes in Patients with Liver Cirrhosis
Background: Ascitic fluid infection (AFI) is the most common bacterial infection in patients with cirrhosis and has several variants, including spontaneous bacterial peritonitis (SBP), bacterascites (BA), and culture-negative neutrocytic ascites (CNNA). Objectives: To date, there has been disagreement about the differences in clinical features and outcomes of these variants of AFI, and there are still few studies in this area. Methods: A cross-sectional study was conducted at a referral hospital from June 2018 to September 2022. All cirrhotic patients with ascites were evaluated for the presence of AFI. Patients with AFI were divided into SBP, BA, and CNNA variants. Non-AFI participants were also evaluated as a comparison group. The outcomes, as well as the clinical and laboratory characteristics of the variants of AFI, were compared. Kaplan-Meier curves and Cox regression analysis were used for survival analysis. Results: A total of 466 patients were studied, of which 132 (28.33%) were in the AFI group and 334 (71.67%) were in the non-AFI group. In the AFI group, 64 (48.48%) had SBP, 43 (32.58%) had CNNA, and 25 (18.94%) had BA. The most common bacteria causing AFI was Escherichia coli. SBP (HR 2.43; 95% CI 1.36 - 4.36; P = 0.003) significantly increased the risk of mortality, while CNNA and BA did not significantly increase this risk. The presence of hepatic encephalopathy and female gender also significantly increased the risk of mortality. Conclusions: The mortality risk was higher in patients with SBP compared to other types of AFI. This study also showed differences in clinical characteristics and laboratory parameters among the three types of AFI. Further research is recommended.
- Open Access
- 1 September 2023
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 55 (5) , 332-334
Extensive arm skin necrosis following administration of unfractionated heparin
Unfractionated heparin (UH), a commonly used anticoagulant, can rarely cause skin necrosis following heparin-induced thrombocytopenia (HIT). A 38-year-old female, a case of chronic inflammatory demyelinating polyneuropathy (CIDP) admitted to the neurology ward, developed extensive skin necrosis following a change in UH dose at the exact site of UH injection. A sudden fall in the platelet count was observed within 48 h of increasing the UH dose. Necrosis of the outer layer of the skin along with clot formation and inflammation in the inner layers was detected after histopathological evaluation. UH was discontinued, and rivaroxaban was started for the patient as soon as the complication was detected. The patient was discharged in good condition after completing treatment for CIDP without any need for surgical removal of the necrotic tissue. Extensive skin necrosis, as a result of HIT, requires immediate discontinuation of UH and substitution of a nonheparin-based anticoagulation treatment.
- 1 September 2023
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 55 (5) , 332-334
Open AccessExtensive arm skin necrosis following administration of unfractionated heparin
Unfractionated heparin (UH), a commonly used anticoagulant, can rarely cause skin necrosis following heparin-induced thrombocytopenia (HIT). A 38-year-old female, a case of chronic inflammatory demyelinating polyneuropathy (CIDP) admitted to the neurology ward, developed extensive skin necrosis following a change in UH dose at the exact site of UH injection. A sudden fall in the platelet count was observed within 48 h of increasing the UH dose. Necrosis of the outer layer of the skin along with clot formation and inflammation in the inner layers was detected after histopathological evaluation. UH was discontinued, and rivaroxaban was started for the patient as soon as the complication was detected. The patient was discharged in good condition after completing treatment for CIDP without any need for surgical removal of the necrotic tissue. Extensive skin necrosis, as a result of HIT, requires immediate discontinuation of UH and substitution of a nonheparin-based anticoagulation treatment.